identif
recurr
human
leukocyt
antigen
hla
neoepitop
drive
cell
respons
tumor
pose
signific
bottleneck
develop
approach
precis
cancer
therapeut
employ
bioinformat
method
predict
cell
epitop
cancer
therapi
analyz
sequenc
data
neuroblastoma
patient
identifi
recurr
anaplast
lymphoma
kinas
mutat
alk
lead
two
high
affin
neoepitop
express
complex
common
hla
allel
analysi
xray
structur
two
peptid
bound
hlab
reveal
drastic
differ
conform
measur
chang
stabil
protein
complex
selfepitop
exclud
bind
due
steric
hindranc
mhc
groov
evalu
rang
hla
allel
could
display
alk
neoepitop
use
structurebas
rosetta
compar
model
calcul
accur
predict
sever
addit
high
affin
interact
compar
result
commonli
use
predict
tool
subsequ
determin
xray
structur
hlaa
bound
neoepitop
valid
atom
featur
seen
rosetta
model
respect
key
residu
relev
mhc
stabil
cell
receptor
recognit
final
mhc
tetram
stain
peripher
blood
mononuclear
cell
hlamatch
donor
show
two
neoepitop
recogn
cell
work
provid
ration
approach
toward
highthroughput
identif
optim
put
neoantigenhla
target
desir
recognit
featur
cancer
immunotherapi
identif
recurr
human
leukocyt
antigen
hla
neoepitop
drive
cell
respons
tumor
pose
signific
bottleneck
develop
approach
precis
cancer
therapeut
employ
bioinformat
method
predict
cell
epitop
cancer
therapi
analyz
sequenc
data
neuroblastoma
patient
identifi
recurr
anaplast
lymphoma
kinas
mutat
alk
lead
two
high
affin
neoepitop
express
complex
common
hla
allel
analysi
xray
structur
two
peptid
bound
hlab
reveal
drastic
differ
conform
measur
chang
stabil
protein
complex
selfepitop
exclud
bind
due
steric
hindranc
mhc
groov
evalu
rang
hla
allel
could
display
alk
neoepitop
use
structurebas
rosetta
compar
model
calcul
accur
predict
sever
addit
high
affin
interact
compar
result
commonli
use
predict
tool
subsequ
determin
xray
structur
hlaa
bound
neoepitop
valid
atom
featur
seen
rosetta
model
respect
key
residu
relev
mhc
stabil
cell
receptor
recognit
final
mhc
tetram
stain
peripher
blood
mononuclear
cell
hlamatch
donor
show
two
neoepitop
recogn
cell
work
provid
ration
approach
toward
highthroughput
identif
optim
put
neoantigenhla
target
desir
recognit
featur
cancer
immunotherapi
keyword
neoepitop
mhc
class
human
leukocyt
antigen
structur
biolog
comput
biolog
cancer
cell
receptor
introduct
cancer
immunotherapi
har
patient
cell
respons
toward
peptid
neoantigen
display
surfac
tumor
cell
major
histocompat
complex
molecul
mhc
term
human
leukocyt
antigen
hla
human
endogen
present
pathway
mhc
class
abundantli
express
intracellular
protein
process
immunoproteasom
proteasom
yield
short
peptid
fragment
transport
endoplasm
reticulum
assembl
togeth
mhci
heavi
chain
light
chain
peptideload
complex
result
peptidemhc
complex
pmhc
traffick
golgi
eventu
display
cell
surfac
surveil
cytotox
cell
ctl
specif
interact
cell
receptor
tcr
process
larg
heterogen
pool
pmhc
antigen
continu
gener
healthi
pathogen
infect
tumor
cell
mean
display
cell
peptid
repertoir
immun
system
display
high
affin
peptid
express
exclus
tumor
ie
neoepitop
mhc
molecul
elicit
specif
ctl
respons
form
basi
sever
establish
immunotherapi
cancer
one
therapi
util
vitroactiv
autolog
ctl
select
target
tumor
cell
altern
vaccin
design
base
known
antigen
ctl
engin
introduc
tcr
desir
specif
toward
display
tumor
antigen
case
neoepitop
deriv
commonli
mutat
oncogen
protein
wellsuit
immunotherapi
target
high
affin
interact
mhc
allel
preval
popul
neuroblastoma
nbl
wide
metastat
form
cancer
affect
develop
nerv
cell
compris
sympathet
nervou
system
primarili
patient
younger
year
old
highrisk
nbl
surviv
rate
less
intens
chemotherapi
radiat
therapi
approv
treatment
addit
patient
respond
posit
radiat
treatment
gener
achiev
longterm
surviv
suffer
cancer
relaps
often
increas
rate
tumor
mutat
sequenc
studi
focus
nbl
stage
indic
wide
spectrum
somat
mutat
tumor
pose
signific
challeng
develop
target
therapeut
notabl
mutat
anaplast
lymphoma
kinas
gene
alk
implic
nbl
case
avail
whole
exom
genom
transcriptom
sequenc
data
target
therapeut
applic
research
gener
effect
treatment
initi
sequenc
data
support
alk
target
highest
mutat
rate
among
highrisk
nbl
patient
furthermor
genom
sequenc
relaps
nbl
tumor
demonstr
retent
alk
mutat
andor
acquisit
alk
mutat
sampl
alk
mutat
shown
hyperactiv
rasmapk
signal
pathway
nbl
drive
cancer
format
recent
studi
also
shown
evid
alk
overexpress
nbl
tumor
make
viabl
target
carmedi
immunotherapi
along
target
cell
therapi
immunotherapi
offer
attract
approach
toward
nbl
treatment
howev
despit
signific
progress
identifi
recurr
mutat
toward
understand
genet
basi
nbl
import
molecular
detail
regard
deriv
neoantigenhla
interact
remain
unknown
limit
develop
target
cell
therapi
use
recent
develop
multilay
bioinformat
pipelin
predict
cell
epitop
cancer
therapi
protect
predict
therapeut
relev
antigen
nbl
tumor
protect
analysi
patient
sampl
nbl
target
cohort
identifi
recur
hotspot
mutat
alk
protein
togeth
specif
toward
common
hla
allel
specif
two
put
peptid
sequenc
mutat
nonam
decam
predict
bind
hlab
high
affin
accord
consensu
method
xray
structur
two
neoepitop
complex
hlab
reveal
drastic
chang
peptid
conform
correl
increas
thermal
stabil
decam
neoepitopehla
complex
selfpeptid
unfavor
interact
peptid
residu
mhcbind
groov
prevent
format
stabl
complex
evalu
potenti
two
alk
neoepitop
interact
addit
hla
allel
predict
structur
featur
relev
recognit
tcr
develop
highthroughput
compar
model
approach
use
program
rosetta
independ
crystallograph
analysi
decamerbound
hlaa
complex
reveal
peptid
conform
fall
extrem
close
rosetta
model
within
backbon
rmsd
final
tetram
stain
peripher
blood
mononuclear
cell
pbmc
hlab
donor
follow
flow
cytometri
analysi
show
two
differ
neoantigen
conform
recogn
cell
taken
togeth
bioinformat
analysi
vitro
structur
character
comput
model
cell
recognit
analysi
illustr
power
approach
toward
highthroughput
identif
optim
broadli
display
put
neoantigenhla
target
develop
toward
cancer
immunotherapi
result
approach
provid
strong
evid
broad
hla
display
recurr
alkderiv
neoantigen
express
nbl
tumor
suggest
present
distinct
neoepitop
conform
hla
groov
could
drive
specif
cell
respons
patient
identif
alk
neoepitop
use
protect
reduc
version
softwar
protect
figur
initi
run
batch
six
primari
relaps
nbl
sampl
pair
target
cohort
find
least
one
neoepitopegen
rate
mutat
persist
relaps
tumor
five
six
patient
tabl
supplementari
data
supplementari
materi
among
two
wellknown
hotspot
mutat
nra
alk
tabl
supplementari
materi
predict
two
hlab
decam
maqdiyrasi
aqdiyrasyy
one
nonam
aqdiyrasi
neoepitop
aris
alk
sampl
predict
bind
affin
better
respect
rel
peptid
background
train
set
top
rank
peptid
consid
true
binder
method
peptid
begin
predict
top
binder
two
epitop
begin
promis
immunolog
perspect
sinc
predict
significantli
better
binder
hlab
parent
selfantigen
ardiyrasyy
percentil
score
ardiyrasi
percentil
score
input
fastq
trio
per
sampl
ultim
give
rise
mhc
haplotyp
provid
list
candid
neoepitop
sampl
abbrevi
td
nd
tumor
normal
dna
respect
tr
tumor
rna
predict
tumornorm
singlenucleotid
variant
snv
filter
peptid
gener
neoepitop
predict
nrang
rang
snv
call
make
past
certain
step
nmed
median
number
call
primari
relaps
pair
run
smaller
modifi
version
pipelin
start
directli
mutat
curat
eleveld
et
al
panel
b
c
show
target
neuroblastoma
cohort
oxog
mutat
level
filter
oxog
artifact
see
predomin
c
ag
mutant
b
wherea
filter
see
mark
reduct
total
number
mutat
balanc
nucleotid
substitut
rate
c
toor
et
al
structur
character
alteredself
nbl
neoepitop
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
use
full
version
protect
softwar
manuscript
prepar
expand
studi
primari
nbl
sampl
target
cohort
collect
complet
statist
alk
neoepitop
identifi
recurr
neoepitop
nbl
tabl
supplementari
data
supplementari
materi
identifi
four
addit
sampl
harbor
alk
panxjl
paptfz
paptlv
none
sampl
express
hlab
sampl
paptfz
display
close
rel
hlab
predict
bind
ardiyrasyy
ardiyrasi
score
respect
two
sampl
panxjl
paptlv
express
highfrequ
hlaa
caucasian
popul
alk
nonam
gmaqdiyra
predict
bind
hlaa
score
six
sampl
harbor
one
nonsynonym
neoepitop
low
percentil
score
least
one
express
hla
allel
among
identifi
recurr
mutat
includ
alk
mutat
present
sampl
respect
mutat
present
three
sampl
tabl
supplementari
materi
one
sampl
cohort
express
nra
activ
mutat
commonli
found
melanoma
thyroid
colorect
cancer
final
nrasderiv
neoepitop
ildtagkeey
aris
singl
mutat
predict
bind
common
hlaa
allel
statist
signific
score
notabl
hlaa
interact
identifi
method
previous
shown
elicit
specif
cell
respons
use
melanoma
cell
line
result
obtain
protect
analysi
provid
rang
therapeut
relev
neoantigenhla
interact
valid
character
use
biophys
structur
method
given
extens
genet
evid
support
role
alk
mutat
nbl
tumor
chose
pursu
interact
alk
hlab
prepar
recombin
hlab
bound
two
alkderiv
neoantigen
nonam
aqdiyrasi
decam
aqdiyrasyy
control
attempt
prepar
hlab
selfantigen
ardiyrasi
predict
reduc
bind
affin
hla
peptidemhc
sampl
refold
purifi
escherichia
coli
inclus
bodi
presenc
molar
excess
peptid
use
standard
method
purifi
size
exclus
chromatographi
sec
sec
trace
nonam
decam
sampl
show
three
distinct
peak
correspond
protein
aggreg
min
pmhc
complex
min
free
min
figur
notabl
sampl
refold
use
selfantigen
peptid
show
two
peak
chromatogram
none
contain
nonaggreg
pmhc
molecul
figur
green
trace
suggest
affin
selfantigen
insuffici
promot
format
stabl
complex
hla
confirm
presenc
neoepitop
two
mhc
sampl
perform
liquid
chromatographymass
spectroscopi
lcm
lcm
reveal
high
rel
abund
correct
peptid
sampl
observ
mass
da
agre
well
expect
mass
nonam
decam
respect
figur
c
thu
confirm
bind
two
tumor
neoepitop
recombin
hlab
prepar
vitro
refold
character
result
pmhc
molecul
use
differenti
scan
fluorimetri
dsf
assay
accur
assess
kinet
stabil
accord
techniqu
properli
fold
class
pmhc
complex
show
melt
temperatur
tm
correl
predict
valu
micromolar
nanomolar
rang
neoantigen
pmhc
sampl
show
clear
unfold
transit
highli
reproduc
tm
nonam
decam
complex
figur
suggest
decam
form
higher
affin
complex
hlab
differ
thermal
stabil
pmhc
complex
togeth
previou
observ
peptid
length
influenc
conform
within
fixedlength
groov
consist
hypothesi
two
peptid
display
via
distinct
bind
mode
previous
report
nonam
decam
peptid
sampl
uniqu
conform
within
mhc
groov
structur
plastic
within
mhc
peptidebind
groov
enabl
distinct
neoantigen
conform
elucid
structur
basi
underli
distinct
stabil
observ
two
alk
neoepitop
character
peptid
featur
display
tcr
solv
xray
structur
nonam
hlab
pdb
id
decam
complex
hlab
aqdiyrasyy
pdb
id
nonam
complex
crystal
space
group
resolut
decam
complex
crystal
space
group
resolut
tabl
supplementari
materi
nonam
peptid
adopt
canon
extend
conform
promot
ntermin
ctermin
anchor
deepli
embed
within
ab
fpocket
hla
groov
figur
b
respect
anchor
result
curv
conform
backbon
residu
push
toward
upper
part
groov
remain
residu
maintain
within
c
e
pocket
figur
survey
previous
deposit
hlab
antigen
pdb
lekargsti
deriv
epsteinbarr
viru
pdb
id
ilgppgsvi
deriv
human
ubiquitinconjug
pdb
id
vqqessfvm
deriv
sar
coronaviru
pdb
id
reveal
nonam
epitop
consist
extend
conform
agreement
conform
alk
nonam
neoepitop
xray
structur
figur
supplementari
materi
furthermor
overal
architectur
b
groov
similar
differ
structur
heavi
atom
backbon
rmsd
less
figur
supplementari
materi
comparison
peptid
amino
acid
sequenc
reveal
excel
agreement
establish
hlab
motif
lmqaeistv
fylm
preferredtoler
anchor
posit
respect
figur
g
supplementari
materi
thu
xray
structur
alkderiv
nonam
neoepitop
consist
establish
structur
featur
pdb
suggest
trend
peptid
backbon
conform
defin
length
anchor
motif
gener
peptid
length
greater
nine
amino
acid
either
bulg
bind
groov
form
zigzag
conform
howev
decam
complex
structur
figur
peptid
adopt
short
helic
backbon
conform
confirm
inspect
backbon
dihedr
angl
figur
supplementari
materi
notabl
ntermin
anchor
residu
ident
nonam
decam
peptid
decam
replac
nonam
ctermin
anchor
residu
similar
conform
figur
accommod
longer
peptid
sequenc
within
fixeds
mhc
groov
thu
achiev
format
compact
helix
decam
rel
extend
nonam
backbon
addit
helix
buri
mhc
groov
creat
amphipath
structur
orient
toward
solvent
figur
structur
superposit
nonam
decam
peptid
backbon
heavi
atom
rmsd
highlight
chang
residu
orient
toward
solvent
suggest
two
epitop
display
differ
surfac
featur
interact
tcr
figur
compact
peptid
backbon
decam
structur
accompani
structur
adapt
mhc
residu
peptidebind
groov
particular
decam
complex
hla
helix
undergo
signific
widen
involv
displac
atom
movement
driven
chang
orient
point
toward
solvent
nonam
versu
toward
groov
decam
complex
figur
b
supplementari
materi
buri
toward
floor
groov
thu
addit
ctermin
tyr
peptid
sequenc
drastic
alter
tertiari
structur
hla
complex
driven
wide
differ
peptid
conform
accommod
conform
plastic
within
malleabl
mhc
groov
key
structur
paramet
extract
crystallograph
analysi
provid
insight
increas
stabil
decamerhla
complex
notabl
buri
surfac
area
bsa
hlab
decam
peptid
rel
nonam
structur
dissect
differ
structur
featur
contribut
pmhc
stabil
analyz
polar
hydrogen
bond
salt
bridg
electrostat
interact
hydrophob
interact
involv
hla
residu
figur
tabl
supplementari
materi
specif
decam
peptid
form
addit
intrapeptid
hydrogen
bond
result
compact
helix
conform
addit
decam
particip
polar
hydrophob
interact
mhc
residu
nonam
form
polar
hydrophob
interact
groov
figur
supplementari
materi
specif
decam
peptid
extend
groov
form
addit
contact
hla
side
chain
figur
c
supplementari
materi
structur
analysi
suggest
increas
total
number
intrapeptid
hydrogen
bond
hydrophob
pack
interact
consist
increas
bsa
brought
compact
helic
conform
lead
improv
stabil
decam
complex
confirm
independ
dsf
experi
figur
structur
exclus
selfantigen
hlab
groov
evalu
potenti
immunogen
alk
neoepitop
compar
affin
hlab
rel
selfpeptid
ardiyrasi
format
stabl
hla
complex
display
selfpeptid
would
compromis
therapeut
relev
relat
neoantigen
due
immun
toler
mechan
limit
repertoir
respons
cell
preliminari
attempt
refold
hlab
use
synthet
nonam
peptid
parent
alk
sequenc
result
effici
pmhc
format
suggest
low
bind
affin
like
micromolar
rang
figur
green
trace
explor
basi
exclus
perform
structur
model
selfpeptidehlab
complex
step
templat
blue
peptidehla
complex
xray
structur
provid
gener
thread
model
peptid
differ
hla
allel
yellow
hla
residu
groov
within
peptid
color
green
step
model
refin
energi
minim
sidechain
repack
groov
peptid
residu
gray
step
averag
peptidebind
energi
determin
subtract
energi
unbound
hla
unbound
peptid
energi
peptid
bound
hla
e
repres
averag
bind
energi
top
lowest
energi
structur
compar
determin
consensu
model
toor
et
al
structur
character
alteredself
nbl
neoepitop
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
use
solv
xray
structur
nonam
complex
templat
find
perform
revers
gln
arg
substitut
lead
steric
hindranc
longer
side
chain
residu
mhcbind
groov
figur
supplementari
materi
despit
care
consider
possibl
arg
sidechain
rotam
signific
clash
remain
helix
well
floor
mhc
groov
figur
supplementari
materi
expect
conserv
peptid
residu
anchor
aand
bpocket
observ
similar
clash
selfdecam
model
hlab
contrast
neoepitop
side
chain
fit
well
bpocket
form
addit
hydrogen
bond
hla
heavi
chain
figur
supplementari
materi
cyan
dot
line
final
perform
detail
structur
model
calcul
use
simultan
optim
peptid
backbon
addit
sidechain
degre
freedom
rank
calcul
affin
three
peptid
hlab
accord
physic
realist
energi
function
selfantigen
complex
yield
least
favor
bind
energi
follow
nonam
final
decam
complex
figur
supplementari
materi
thu
structur
analysi
highli
consist
vitro
result
ie
selfpeptid
exclud
bind
sharp
contrast
nonam
decam
neoepitop
form
tight
complex
hla
evalu
hlabind
repertoir
use
compar
model
calcul
patient
hla
haplotyp
play
major
role
determin
outcom
target
cancer
immunotherapi
therefor
toward
expand
rang
individu
could
mount
cell
respons
alk
neoepitop
evalu
potenti
hla
display
two
peptid
silico
develop
appli
highthroughput
approach
exploit
avail
highresolut
xray
structur
two
neoepitop
simultan
predict
peptidehla
interact
surfac
featur
peptid
residu
pois
interact
tcr
first
select
nonredund
set
hla
allel
hlaa
hlab
hlac
uniqu
sequenc
emblebi
databas
carri
detail
rosetta
compar
model
calcul
allel
use
experiment
determin
hlab
structur
nonam
decam
alk
peptid
templat
figur
contrast
previou
structurebas
peptidehla
model
method
use
flexibl
peptid
dock
approach
use
fixedpeptid
backbon
thread
approach
follow
energi
minim
interact
peptid
hla
residu
drastic
confin
dock
degre
freedom
approach
motiv
observ
peptid
backbon
conform
show
minim
varianc
less
rmsd
nonam
hlab
structur
report
pdb
figur
supplementari
materi
use
strategi
extract
highli
reproduc
bind
energi
nonam
decam
peptid
maintain
extend
helic
conform
respect
result
model
total
hla
allel
b
c
type
exhibit
lower
bind
energi
nonam
decam
peptid
initi
hlab
structur
templat
figur
figur
supplementari
materi
red
squar
suggest
potenti
broader
hla
display
repertoir
elucid
sequenc
bia
specif
residu
hlabind
groov
consist
yield
favor
interact
two
peptid
analyz
averag
bind
energi
function
sequenc
ident
score
calcul
rel
best
bind
allel
peptid
figur
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
neg
control
comput
bind
energi
mock
hla
allel
residu
mhcbind
groov
mutat
ala
expect
mock
polyala
hla
exhibit
low
bind
affin
ie
highbind
energi
peptid
distant
best
bind
allel
figur
figur
supplementari
materi
green
triangl
top
left
observ
figur
evalu
human
leukocyt
antigen
hla
bind
repertoir
alk
decam
aqdiyrasyy
use
rosetta
structurebas
model
rosettabind
energi
calcul
structur
model
uniqu
hla
allel
ipdimgthla
databas
alk
neoepitop
decam
aqdiyrasyy
plot
function
sequenc
similar
top
bind
allel
hlab
black
circl
bind
energi
decam
hlab
xray
structur
shown
refer
red
squar
neg
control
perform
mock
hla
allel
residu
bind
groov
replac
ala
polyala
groov
green
triangl
show
highbind
energi
correspond
distribut
hla
allel
bind
energi
landscap
captur
densiti
plot
shown
right
sequenc
ident
score
calcul
use
test
valid
structurebas
simul
perform
vitro
refold
alkderiv
nonam
decam
peptid
hlaa
allel
chosen
highfrequ
allel
multipl
popul
worldwid
previous
shown
form
stabl
recombin
pmhc
complex
structur
character
observ
previou
experi
hlab
figur
figur
figur
supplementari
materi
although
certain
hla
mhc
allel
previous
report
yield
partial
fold
peptidefre
molecul
measur
thermal
stabil
control
refold
experi
perform
without
peptid
hla
allel
fail
yield
stabl
complex
final
conclus
test
atom
featur
predict
simul
determin
xray
structur
decam
complex
hlaa
pdb
id
decam
complex
crystal
group
resolut
tabl
supplementari
materi
inspect
crystallograph
dihedr
angl
reveal
peptid
backbon
also
adopt
short
helix
conform
bound
hlaa
suggest
peptid
length
main
determin
conform
groov
justifi
fixedbackbon
model
approach
figur
supplementari
materi
peptid
conform
xray
structur
show
excel
agreement
rosetta
model
backbon
heavi
atom
rmsd
sever
highresolut
featur
predict
model
confirm
xray
includ
polar
contact
within
aand
fpocket
mhc
groov
figur
figur
supplementari
materi
specif
sidechain
hydroxyl
group
peptid
contact
tyr
ly
trp
sidechain
atom
fpocket
figur
f
final
comparison
xray
structur
peptid
bound
hlab
side
chain
flip
outward
groov
bound
hlaa
alter
peptid
surfac
display
tcr
figur
e
supplementari
materi
thu
independ
xray
structur
corrobor
trend
observ
structurebas
bind
energi
simul
support
potenti
hla
molecul
display
recurr
alk
neoepitop
uniqu
tcr
interact
properti
two
alkderiv
neoepitop
recogn
cell
given
uniqu
conform
surfac
featur
observ
nonam
decam
peptid
sought
determin
whether
two
alteredself
ie
mutat
neoantigen
could
recogn
cell
use
mhc
tetram
stain
assay
follow
multichannel
flow
cytometri
analysi
hypothes
hlamatch
donor
would
abl
recogn
structur
character
alteredself
nbl
neoepitop
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
alteredself
neoepitop
peripheri
long
peptid
adopt
conform
potenti
interact
tcr
test
acquir
pbmc
two
hlab
healthi
donor
peptid
perform
doubl
stain
experi
use
hlab
tetram
conjug
allophycocyanin
apc
phycoerythrin
pe
toward
identif
cell
recogn
neoepitop
final
cell
sort
use
fluorescencebas
detect
result
identif
doubl
posit
popul
total
cell
reactiv
nonam
figur
supplementari
materi
reactiv
decam
epitop
figur
supplementari
materi
notabl
find
similar
two
independ
stain
experi
use
pbmc
individu
donor
figur
immunotherapi
stimul
immun
system
attack
tumor
includ
immun
checkpoint
blockad
adopt
cell
therapi
achiev
spectacular
result
tumor
type
high
mutat
burden
melanoma
howev
util
tumor
lower
mutat
burden
occur
pediatr
cancer
less
clear
develop
target
cell
base
immunotherapi
treat
cancer
reli
understand
molecular
basi
neoepitop
display
tumor
cell
addit
initi
regul
cytotox
cell
respons
current
roadblock
develop
robust
approach
across
patient
hla
locu
extrem
polymorph
individu
exact
hla
haplotyp
sculpt
repertoir
epitop
display
immun
system
moreov
identif
therapeut
relev
antigen
tumor
remain
extrem
challeng
complic
fact
singl
hla
allel
potenti
bind
distinct
peptid
epitop
tradit
vitro
measur
affin
mhc
potenti
antigen
achiev
equilibrium
dialysi
fluoresc
polar
experi
recent
approach
allow
global
evalu
entir
peptid
repertoir
use
mass
spectroscopi
mhc
complex
extract
cell
line
express
singl
hla
allel
follow
bioinformat
analysi
robust
altern
strategi
identifi
character
neoepitopehla
complex
desir
cell
recognit
featur
would
significantli
bolster
progress
target
cell
therapi
cancer
recent
develop
protect
fulli
autom
freeli
avail
tool
predict
express
neoepitop
base
somat
mutat
present
tumor
sampl
nbl
common
pediatr
cancer
protect
analysi
identifi
rang
intrigu
predict
high
affin
neoepitopehla
target
examin
futur
studi
nra
tabl
supplementari
materi
includ
alk
neoepitop
examin
detail
typic
immun
epitop
databas
iedb
base
bind
predict
method
bias
toward
nonam
peptid
due
limit
number
dataset
peptidemhcbind
affin
measur
shorter
longer
peptid
length
moreov
affin
threshold
bind
base
valu
hla
allel
specif
rang
nm
could
result
fals
neg
predict
weak
bind
epitop
may
immunogen
consid
attempt
normal
limit
protect
use
suit
predictor
train
combin
andor
allelespecif
dataset
consid
rang
epitopebind
affin
analysi
find
nbl
sampl
one
predict
high
affin
neoepitopehla
target
sought
character
natur
pmhc
interact
result
rel
common
alk
mutat
lay
groundwork
develop
target
immunotherapi
develop
pipelin
evalu
promis
tumor
neoepitop
toward
goal
elucid
structur
characterist
underli
vitro
stabil
present
two
alk
nonam
decam
epitop
correspond
selfpeptid
bind
hla
groov
addit
develop
appli
highthroughput
compar
model
approach
identifi
addit
hla
allel
could
display
two
neoepitop
predict
structur
high
accuraci
toward
understand
link
peptid
surfac
featur
interact
tcr
final
examin
potenti
alkderiv
neoepitopehla
complex
activ
immun
respons
analyz
cell
recognit
hlab
donor
exact
conform
dynam
featur
peptid
within
mhcibind
groov
known
play
pivot
role
recognit
cell
dictat
mhcpeptidebind
affin
stabil
cell
surfac
crossreact
interact
specif
tcr
molecul
xray
structur
reveal
extrem
case
conform
plastic
addit
singl
ctermin
tyr
neoantigen
sequenc
aqdiyrasi
aqdiyrasyy
significantli
alter
peptid
conform
figur
dramat
chang
rel
canon
extend
structur
highlight
format
helix
span
residu
figur
supplementari
materi
provid
link
peptid
conform
hla
complex
stabil
specif
helix
lead
increas
bsa
number
molecular
interact
peptid
hla
side
chain
figur
supplementari
materi
agreement
increas
thermal
stabil
figur
addit
observ
chang
hla
groov
includ
displac
helix
undergo
signific
widen
involv
movement
atom
figur
b
supplementari
structur
character
alteredself
nbl
neoepitop
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
materi
result
support
import
helix
particip
myriad
immun
process
chaperonemedi
peptid
loadingedit
allelespecif
antigen
present
tcr
recognit
context
conform
plastic
mhc
groov
accommod
epitop
vari
length
final
structur
model
selfantigen
sequenc
agreement
vitro
refold
experi
show
sharp
contrast
stabil
rel
neoantigen
due
arg
anchor
accommod
either
extend
helic
backbon
conform
result
provid
ration
approach
improv
neoepitop
hla
complex
stabil
halflif
cell
surfac
rel
unstabl
selfepitopehla
complex
optim
peptid
backbon
conform
addit
anchor
residu
interact
could
ultim
lead
select
effici
neoantigen
consist
previou
studi
show
abil
tumor
antigen
induc
cell
respons
prevent
tumor
relaps
correl
pmhc
stabil
cancer
patient
harbor
tumorspecif
mutat
result
neoepitop
hla
haplotyp
would
extrem
benefici
expand
repertoir
hla
molecul
bind
present
given
therapeut
target
sequencebas
tool
avail
iedb
provid
highli
reliabl
predict
epitop
bind
rang
hla
allel
structur
detail
predict
epitopehla
complex
relev
interact
tcr
provid
method
complementari
method
use
model
interact
within
peptidehla
complex
leverag
highresolut
structur
data
avail
pdb
approach
employ
flexibl
peptid
dock
construct
sequenc
specif
profil
explor
differ
peptidehla
combin
util
compar
model
approach
fixedpeptid
backbon
allow
sidechain
flexibl
within
hla
groov
screen
larg
pool
hla
allel
bind
alkderiv
nonam
decam
neoantigen
figur
figur
supplementari
materi
highrank
hla
allel
accord
rosetta
bind
energi
consist
demonstr
low
percentil
rank
use
epitop
predict
method
recommend
iedb
suggest
high
probabl
form
tight
complex
neoepitop
figur
supplementari
materi
subsequ
test
bind
predict
show
nonam
decam
peptid
form
stabl
complex
common
hlaa
vitro
albeit
decreas
stabil
compar
hlab
bound
complex
figur
figur
supplementari
materi
accuraci
rosetta
model
highlight
comparison
decamerhlaa
xray
structur
show
backbon
rmsd
tabl
figur
supplementari
materi
fixedbackbon
approach
support
observ
conform
peptid
backbon
maintain
among
xray
structur
contain
differ
high
affin
nonam
peptid
bound
hlab
figur
supplementari
materi
moreov
comparison
decam
peptid
conform
bound
hlab
versu
hlaa
two
allel
share
groov
residu
accord
pairwis
sequenc
align
show
modest
chang
backbon
rmsd
tabl
supplementari
materi
stark
contrast
observ
signific
conform
chang
nonam
decam
peptid
crystallograph
complex
hlab
allel
backbon
rmsd
result
suggest
peptid
length
defin
backbon
conform
conserv
anchor
residu
interact
within
fixeds
class
mhc
groov
featur
peptid
bind
allow
us
confid
model
patientspecif
neoepitopehla
interact
highthroughput
manner
use
singl
crystal
structur
contain
peptid
templat
final
approach
allow
us
predict
surfac
featur
neoepitop
hla
complex
avail
interact
tcr
molecul
toward
evalu
immunogen
within
current
scope
method
rosetta
account
conform
plastic
within
mhc
groov
allow
sidechain
rotam
limit
backbon
flexibl
thu
accur
model
epitop
bind
achiev
given
templat
contain
mhc
groov
accommod
fixedpeptid
length
ie
model
nonam
epitop
templat
xray
structur
nonamerhla
complex
use
howev
current
protocol
account
larg
chang
backbon
groov
may
requir
model
peptid
shorter
longer
length
futur
improv
structurebas
predict
procedur
account
may
achiev
use
rosetta
compar
model
rosettacm
hybrid
rosettaremodel
screen
cell
could
recogn
tumor
neoantigen
focus
analysi
lymphocyt
sampl
healthi
donor
identifi
popul
cell
recogn
two
alk
neoepitop
highli
specif
manner
minimum
crossreact
figur
supplementari
materi
observ
approxim
half
frequenc
reactiv
cell
hlab
tetram
rel
frequenc
observ
hlab
decam
tetram
figur
supplementari
materi
may
suggest
differ
cell
recognit
two
epitop
addit
percentag
reactiv
cell
two
neoepitop
compar
valu
observ
immunodomin
sar
epitop
figur
supplementari
materi
nomin
frequenc
cell
specif
pmhc
molecul
rang
observ
valu
hlab
tetram
within
rang
specif
cell
identifi
previou
report
pbmc
stain
healthi
donor
use
hlab
tetram
stain
result
support
recognit
put
nonam
decam
neoepitop
cell
potenti
abil
epitop
drive
specif
immun
respons
engag
tcr
molecul
trigger
signal
cell
driven
interact
tcr
complementaritydetermin
region
specif
peptidehla
structur
motif
detail
structur
character
provid
insight
uniqu
featur
give
rise
distinct
interfac
chemistri
display
two
neoepitop
like
interplay
hla
complex
stabil
peptid
surfac
featur
guid
engag
pool
two
neoantigen
futur
studi
group
aim
identifi
tcr
structur
character
alteredself
nbl
neoepitop
frontier
immunolog
wwwfrontiersinorg
januari
volum
articl
recogn
hla
display
alk
neoepitop
toward
goal
character
interfac
pmhctcr
complex
structur
character
alk
pmhctcr
complex
allow
us
understand
conform
plastic
observ
nonam
decam
neoepitop
dictat
cell
recognit
toward
foster
develop
pmhctcr
complex
improv
stabil
immunolog
synaps
summari
outlin
novel
approach
toward
robust
highthroughput
identif
detail
character
highli
stabl
put
neoantigenhla
target
desir
cell
recognit
featur
cancer
immunotherapi
recent
establish
technolog
enabl
highthroughput
parallel
detect
cell
specif
wide
spectrum
epitop
combinatori
encod
pmhc
multim
method
alreadi
appli
monitor
preval
cell
reactiv
establish
tumor
epitop
addit
vaccin
cancer
patient
display
neoantigen
elicit
broad
cell
respons
term
specif
clonal
divers
success
futur
cancer
immunotherapi
base
technolog
depend
abil
finetun
desir
cell
respons
toward
specif
tumor
epitop
data
suggest
malleabl
structur
featur
target
neoepitopemhc
complex
har
achiev
finetun
thu
character
recur
cellreact
neoepitop
togeth
hla
specif
molecular
determin
stabil
provid
new
screen
tool
therapeut
target
enabl
develop
person
immunotherapi
nbl
tumor
one
hundr
nbl
sequenc
trio
normal
tumor
dnaseq
tumor
rnaseq
download
nation
cancer
institut
genom
data
common
ncigdc
use
gdc
data
transfer
tool
sampl
download
bam
format
convert
back
nativ
pair
fastq
format
use
picard
samtofastq
modul
rnaseq
bam
file
read
pair
map
separ
read
group
file
convert
fastq
use
inhous
python
script
process
sampl
raw
fastq
trio
neoepitop
predict
rate
hsampl
four
microsoft
azur
machin
supplementari
data
supplementari
materi
mhc
haplotyp
mhc
class
mhc
class
ii
call
sequenc
data
use
phlat
haplotyp
sampl
decid
base
consensu
decis
three
input
haplotyp
somat
point
mutat
call
use
panel
five
mutat
caller
mutect
muse
radia
somaticsnip
strelka
sinc
mutat
caller
dna
centric
allow
mutat
reject
two
caller
first
filter
vcf
firstpass
mutant
subject
snpeff
use
index
http
githubcomarkalrandomprocessrgspi
gener
gencod
annot
accept
mutat
filter
stringent
use
inhous
tool
transgen
translat
mutant
peptid
librari
construct
sequenc
induc
artifici
oxid
guanin
base
oxog
caus
highenergi
sonic
oxog
base
pair
thymin
pcr
instead
regular
pair
partner
cytosin
result
low
allel
fraction
g
c
substitut
seen
predominantli
read
read
respect
fastq
transgen
filter
variant
aris
sole
form
read
read
align
low
allelefract
mutant
allel
fraction
rnaseq
coverag
sinc
nonexpress
protein
never
pick
adapt
immun
system
filter
event
low
rnaseq
coverag
mutat
filter
posit
evid
rna
unexpress
alt
allel
read
span
across
none
cover
posit
splice
variant
gene
unexpress
filter
mutant
translat
peptid
length
n
use
gencod
protein
code
translat
correspond
annot
use
transcriptspecif
peptid
gener
account
known
splice
variant
peptid
gener
transgen
test
bind
infer
hla
haplotyp
use
iedb
suit
mhci
mhcii
epitop
predictor
input
peptid
yield
n
call
allel
hla
haplotyp
n
mhci
n
mhcii
call
repres
combin
consensu
percent
score
peptid
number
iedb
algorithm
train
mhc
allel
method
includ
artifici
neural
network
stabil
matrix
method
method
use
bind
motif
obtain
combinatori
librari
etc
method
return
percent
rank
input
peptid
mhc
combin
versu
background
set
gener
iedb
consensu
score
call
median
score
across
method
call
peptid
consensu
percent
score
greater
ie
binder
wors
top
background
set
filter
nonbind
peptid
consensu
percent
rank
greater
ie
binder
wors
top
background
set
filter
nonbind
rank
selfpeptid
filter
mutant
calcul
use
method
peptid
group
mutat
transcript
origin
immunoact
region
iar
ie
region
like
produc
peptid
stimul
immun
system
iar
rank
base
affin
best
contain
binder
express
transcript
origin
promiscu
region
predict
number
mhc
stimul
peptid
iar
number
iar
overlap
bind
mhc
similar
affin
initi
pilot
rnaseq
bam
six
primari
relaps
pair
sampl
download
gdc
run
reduc
version
pipelin
use
vcf
file
gener
supplementari
data
eleveld
et
al
contain
predict
mutat
mhc
haplotyp
sampl
decid
base
consensu
call
primari
relaps
rnaseq
sampl
run
version
protect
pipelin
freeli
avail
docker
version
http
quayiorepositoryucsccglprotect
microsoft
azur
cpu
ram
disk
cpu
ram
disk
hlab
hlaa
gene
contain
bira
tag
clone
plasmid
provid
us
nih
tetram
core
facil
vitro
experi
prepar
purifi
molecul
xray
crystallographi
use
solubl
version
mhc
heavi
chain
lack
bira
tag
site
direct
mutagenesi
remov
bira
tag
perform
use
quikchang
lightn
multisit
kit
agil
follow
manufactur
instruct
result
dna
encod
hlab
heavi
chain
hlaa
heavi
chain
human
light
chain
transform
e
coli
novagen
express
inclus
bodi
refold
use
previous
describ
method
briefli
e
coli
growth
autoinduct
pellet
centrifug
resuspend
ml
bugbust
milliporesigma
per
liter
cultur
cell
lysat
sonic
subsequ
pellet
centrifug
g
min
collect
inclus
bodi
inclus
bodi
resuspend
ml
wash
buffer
mm
tri
ph
mm
edta
vv
deoxychol
sonic
centrifug
inclus
bodi
resuspend
ml
te
buffer
mm
tri
ph
mm
edta
sonic
centrifug
follow
inclus
bodi
solubil
ml
resuspens
buffer
mm
tri
ph
mm
edta
mm
dtt
guanidinehcl
solubil
inclus
bodi
heavi
chain
light
chain
mix
ratio
ad
dropwis
day
l
refold
buffer
mm
tri
ph
mm
edta
arginin
hcl
mm
lglutathion
reduc
mm
lglutathion
oxid
contain
mg
synthet
peptid
biopeptik
refold
perform
day
without
stir
sampl
exhaust
dialyz
sec
buffer
mm
tri
ph
mm
nacl
follow
sampl
concentr
labscal
tff
system
ml
concentr
final
volum
ml
use
amicon
centrifug
kda
cutoff
filter
unit
millapor
sigma
purif
perform
use
sec
hiload
superdex
pg
run
buffer
mm
tri
ph
mm
nacl
follow
anion
exchang
chromatographi
use
mono
q
gl
column
gradient
buffer
mm
tri
ph
mm
nacl
buffer
b
mm
tri
ph
nacl
final
purifi
protein
exhaust
buffer
exchang
mm
sodium
phosphat
ph
mm
nacl
final
sampl
valid
use
lcm
ltqorbitrap
velo
pro
ms
instrument
confirm
presenc
bound
peptid
hlab
contain
bira
tag
refold
togeth
either
synthet
produc
aqdiyrasi
aqdiyrasyy
peptid
biopeptik
purifi
follow
method
describ
earlier
purifi
protein
concentr
mgml
biotinyl
use
bira
biotinprotein
ligas
bulk
reaction
kit
avid
cat
bulk
bira
follow
manufactur
instruct
sdspage
gel
shift
assay
perform
confirm
effici
biotinyl
reaction
accord
previous
publish
protocol
biotinyl
protein
sampl
concentr
split
two
approxim
aliquot
streptavidinp
tetram
mgml
streptavidinrphycoerythrin
prozym
cat
ad
time
interv
min
streptavidinapc
tetram
mgml
streptavidinallophycocyanin
prozym
cat
ad
time
interv
min
final
tetram
sampl
store
purifi
hlab
hlab
hlaa
complex
lack
bira
biotinyl
tag
use
crystal
protein
concentr
mgml
mm
nacl
mm
tri
ph
crystal
tray
set
use
proteintobuff
ratio
room
temperatur
hlab
small
crystal
appear
initi
screen
use
molecular
dimens
jcsgplu
screen
day
mm
hepe
ph
peg
optim
diffract
qualiti
crystal
harvest
incub
condit
plu
al
oil
cryoprotect
flashfrozen
liquid
nitrogen
data
collect
diamond
shape
diffract
qualiti
crystal
grown
crystal
buffer
contain
mm
hepe
ammonium
sulfat
peg
diffract
qualiti
crystal
hlaa
grown
magnesium
chlorid
sodium
hepe
ph
vv
vv
glycerol
crystal
flashfrozen
liquid
nitrogen
buffer
contain
crystal
condit
supplement
glycerol
crystal
use
studi
grown
use
hang
drop
vapor
diffus
method
data
collect
singl
crystal
cryogen
condit
advanc
light
sourc
beam
line
diffract
imag
index
integr
scale
use
mosflm
scala
packag
structur
determin
phaser
use
previou
structur
hlab
pdb
id
hlaa
pdb
id
search
model
model
build
refin
perform
use
coot
phenix
respect
dsf
experi
perform
use
appli
biosystem
viia
qpcr
machin
excit
emiss
wavelength
nm
nm
respect
accord
previous
describ
protocol
sampl
run
triplic
total
volum
use
wellplat
format
protein
buffer
exchang
assay
buffer
mm
sodium
phosphat
ph
mm
nacl
individu
well
contain
final
concentr
respect
protein
sypro
orang
dye
thermofish
determin
thermal
stabil
sampl
temperatur
increment
increas
scan
rate
data
analysi
perform
use
graphpad
prism
melt
temperatur
tm
determin
fit
melt
curv
boltzmann
sigmoid
fit
structur
character
alteredself
nbl
neoepitop
side
chain
consid
manual
rotam
give
lowest
strain
use
final
structur
model
figur
supplementari
materi
peptidemhcbind
energi
comput
use
rosetta
softwar
suit
averag
bind
energi
residuespecif
interact
calcul
use
residueenergybreakdown
protocol
rosetta
assess
abil
alk
neoepitop
bind
hla
allel
perform
homologybas
structur
simul
comput
pmhcbind
energi
silico
outlin
method
present
figur
threedimension
structur
model
comput
pmhcbind
affin
perform
use
rosetta
softwar
suit
see
text
footnot
carri
model
homolog
hla
allel
use
rosettacm
protocol
process
model
highresolut
protein
structur
use
rosettacm
primarili
requir
sequenc
homolog
align
sequenc
relat
known
structur
subsequ
follow
gener
predict
structur
use
restraint
guid
mont
carlo
sampl
strategi
perform
structur
simul
hla
allel
use
hlab
xray
structur
templat
carri
local
refin
peptid
mhcbind
groov
kept
backbon
atom
fix
allow
conform
freedom
sidechain
residu
mhcbind
groov
defin
hla
residu
within
peptid
local
structur
refin
allow
minim
steric
clash
introduc
rosettacm
protocol
addit
refin
peptid
mhcbind
groov
model
avoid
nois
fullatom
refin
might
introduc
tri
minim
energi
landscap
region
henc
make
difficult
extract
accur
pmhcbind
energi
local
refin
stage
gener
pool
refin
structur
sampl
low
bind
energi
highbind
affin
structur
averag
bind
energi
evalu
use
rosetta
energi
function
comput
bind
energi
perform
follow
step
trim
mhc
pdb
file
remov
domain
domain
form
peptidebind
groov
retain
perform
local
refin
mhcbind
groov
peptid
use
rosetta
relax
protocol
allow
region
focu
local
optimum
rosetta
forc
field
use
relax
protocol
obtain
pool
local
refin
model
comput
bind
energi
relax
model
use
interfaceanalyz
protocol
separ
mhc
peptid
energi
contribut
subtract
energi
bound
pmhc
select
lowest
bind
energi
model
report
averag
bind
http
wwwrosettacommonsorg
energi
sequenc
ident
score
comput
use
matrix
hla
allel
show
sequenc
similar
perform
simul
obtain
hla
sequenc
european
bioinformat
institut
ipdimgthla
databas
use
clustalomega
perform
multipl
sequenc
align
hla
allel
convert
align
rosetta
intern
align
format
homolog
model
kullbackleibl
sequenc
logo
gener
previous
describ
rosetta
simul
perform
ucsc
baker
cluster
use
comput
node
core
per
comput
node
amd
opteron
tm
ghz
processor
total
time
use
model
hla
sequenc
approxim
core
hour
cryopreserv
pbmc
ctl
two
healthi
independ
nonpool
hlab
donor
thaw
rest
phenol
red
free
media
supplement
fb
lglut
penstrep
least
h
four
independ
pbmc
stain
experi
run
donor
pbmc
use
nonamerhlab
decamerhlab
sarshlab
doubl
stain
experi
pbmc
use
decamerhlab
nonamerhlab
experi
rest
period
cell
wash
pb
follow
stain
tetram
min
aqua
aminereact
dye
invitrogen
ad
min
assess
cell
viabil
follow
addit
antibodi
cocktail
stain
surfac
marker
addit
min
cell
wash
fac
buffer
pb
contain
sodium
azid
bsa
sort
use
aria
c
flow
cytomet
analysi
percentag
reactiv
cell
perform
follow
gate
forwardsid
scatter
live
lymphocyt
gate
live
cell
gate
cell
refin
coordin
structur
factor
xray
structur
hlab
hlab
hlaa
complex
deposit
protein
data
bank
wwwrcsborg
pdb
id
respect
protect
pipelin
avail
use
apach
licens
academ
user
http
